Organization
Alessandria
1 abstract
Abstract
Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016).Org: Reggio Emilia, Potenza, Italy - Reggio Emilia, Vimercate, Experimental Clinical Abdominal Oncology Unit,